Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

XGN - Exagen Inc. So'nggi Yangiliklar | Finranks

Home

/

XGN

E

Exagen Inc. (XGN)

NGM – Real vaqt narxi. Valyuta: USD

6.63

-0.14 (-2.14%)

Bozor ochiq: Aug 12, 2026, 11:53 AM EDT

6.80

+0.03 (0.44%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Exagen Q2 Earnings Call Highlights

Exagen Q2 Earnings Call Highlights

Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. Reports Second Quarter 2026 Financial Results

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.

Videolar

No Data

There is no data to display

Press-relizlar

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. Reports Second Quarter 2026 Financial Results

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.